What should a laboratory verify before they buy KPV Australia?
When a laboratory decides to buy KPV Australia, the purchase should be executed against a written specification covering identity, chromatographic purity, net peptide content, salt form and lot documentation. The intended chemical entity is the tripeptide Lys-Pro-Val. Independent publications identify that residue string as α-MSH(11–13), the carboxyl-terminal tripeptide of α-melanocyte-stimulating hormone, which is a structural definition of the analyte rather than a statement of laboratory application (PMID:15102092; PMID:21222263). Request, before payment is released, the lot number that will be shipped, a method summary for the purity HPLC (stationary phase, detection wavelength, gradient window), the observed m/z assigned to the protonated molecule, the reported area-percent purity, the counter-ion, and either net peptide content or an orthogonal peptide assay.
Short peptides are commonly isolated as trifluoroacetate or acetate salts and retain variable water. A vial mass expressed only in milligrams is a gross mass; without water and counter-ion values it cannot be converted to peptide mass. Confirm that the CoA lot identifier is identical to the vial label and that a chromatogram or batch report exists for that lot rather than a recycled template.
Australian research procurement adds records that sit alongside the chemistry: a local stock position so the evaluated lot is the lot received, a tracked dispatch identifier for chain-of-custody filing, and archival of the CoA with incoming-goods documentation. Listings that omit sequence, molecular weight, HPLC purity or a lot number are not analytically specified. Prefer vendors who release per-lot HPLC and MS data. Research-only supply means the peptide is a laboratory reagent, not a therapeutic good.
How is KPV identity confirmed as the α-MSH(11–13) tripeptide Lys-Pro-Val?
Identity testing for KPV is a sequence-and-mass problem, not a brand-name problem. The residue order Lys-Pro-Val is the chemical definition of the analyte; melanocortin peptide papers number that motif as α-MSH(11–13), locating KPV as the three C-terminal residues of the parent tridecapeptide (PMID:15102092; PMID:12851308). That numbering is used here solely to lock the primary structure the laboratory must verify. Electrospray ionisation mass spectrometry should report a singly charged ion consistent with the free-base molecular formula of Lys-Pro-Val, reconciled to the theoretical monoisotopic mass, with sodium or potassium adducts annotated rather than left unidentified.
Tandem MS should yield b and y ions mapping the Lys–Pro and Pro–Val bonds. Proline-directed fragmentation is often intense; the spectrum must still exclude sequence isomers PKV and VKP and deletion peptides KV, KP and PV. Amino-acid analysis after hydrolysis is an orthogonal identity method: lysine, proline and valine should be recovered in an equimolar ratio within method uncertainty.
Catalogue nomenclature is not identity. The CoA should print the sequence, a molecular formula or exact mass, and the lot. Reductive glycoalkylation of the lysine residue produces analogues that retain much of the Pro–Val motif but are not parent KPV (PMID:29953505). Identity methods must flag Nε-modified species rather than accepting a UV peak by default. Record instrument type, ionisation mode and calibration reference. A nominal-mass scan is weaker than accurate-mass measurement, but either is superior to HPLC area-percent alone. Counter-ion does not change the peptide molecular ion after desalting, but it does change the solid’s formula weight used for net content. Identity and assay remain separate CoA lines.
Why does HPLC peak purity for KPV require low-wavelength detection and orthogonal MS?
KPV contains lysine, proline and valine only. It has no phenylalanine, tyrosine or tryptophan, so absorbance at 280 nm is not a usable purity signal. Reversed-phase HPLC with ultraviolet detection at approximately 210–220 nm, where the peptide bond absorbs, is the practical chromatographic purity method. The tripeptide is polar and may elute near the void on a C18 column unless an ion-pairing modifier such as trifluoroacetic acid is used to increase retention and improve peak shape. Method documentation should state column chemistry, particle size, dimensions, column temperature, mobile-phase composition, gradient table, flow rate, sample volume applied to the column, sample diluent and detection wavelength. Without those parameters, an area-percent purity cannot be compared between lots or suppliers.
Diode-array peak-purity algorithms that rely on spectral contrast are less informative for KPV than for aromatic peptides, because related substances share a similar peptide-bond UV spectrum. Coupling HPLC to mass spectrometry is the appropriate orthogonal check that the integrated UV peak corresponds to the Lys-Pro-Val mass.
Related substances include synthesis deletions, D-residue epimers at C-terminal valine, Nα- or Nε-acyl lysine species, and diketopiperazine from the X-Pro motif. Chromatographic purity is an area-percent at a stated wavelength, not net peptide content. System suitability belongs in the batch record: blank response, resolution to the nearest related substance, tailing factor, and replicate peak-area precision. Laboratories that buy KPV Australia as a chromatographic marker should archive the chromatogram PDF and method ID, not only the headline purity integer. If a supplier reports purity without wavelength or chromatogram, the figure is not reviewable. Relative retention times for specified related substances should be reported so that later lots can be compared on the same method ID.
Which CoA fields and lot-traceability records belong with an Australian KPV purchase?
A research CoA for KPV should bind one manufacturing lot to a defined set of results. Minimum fields are: unique lot identifier; appearance (commonly a lyophilised solid); printed sequence (Lys-Pro-Val or KPV) and molecular weight or formula; HPLC purity with method identifier and detection wavelength; mass-spectrometric identity with observed m/z; counter-ion; and, where performed, water by Karl Fischer titration and residual solvents. Net peptide content or an equivalent peptide assay should be present if the laboratory will prepare gravimetric solutions. The lot printed on the CoA must match the vial label and the dispatch note; mismatched identifiers are a quarantine event.
Lot traceability for an Australian purchase means a reviewer can reconstruct which analytical files belong to which vial. Multi-vial orders are analytically cleaner when every vial is filled from one lot covered by one HPLC/MS package. Mixed lots require multiple CoAs. Batch reports should include the chromatographic run sequence—blank, system-suitability standard, sample—so that carry-over and integration decisions can be audited.
Documentation should state that the material is a research chemical for laboratory investigation. Australian research supply is distinct from therapeutic-goods supply; this page does not present KPV as a registered medicine. Incoming inspection should check container closure, label concordance, and that the CoA is lot-specific. Retain electronic copies of the chromatogram, mass spectrum and CoA.
Tracked dispatch contributes a consignment identifier for chain-of-custody records. Local AU stock reduces the likelihood that the lot evaluated at enquiry is substituted at pick. If a label states acetate, an acetate assay and a residual trifluoroacetate value should support that claim when the peptide was cleaved in TFA. Peptide content, HPLC purity and identity are three different quality attributes and should not be collapsed into a single marketing percentage.
How do lysine-side-chain modifications and related substances affect KPV characterisation?
The lysine residue is the principal reactive site on KPV and therefore the principal source of both intentional analogues and process-related substances. Songok and co-workers described reductive glycoalkylation of that lysine, generating structurally modified KPV species whose masses and chromatographic retention diverge from the parent tripeptide while retaining much of the Pro–Val motif (PMID:29953505). For quality control, the ε-amino group can participate in Schiff-base formation, reductive alkylation and acylation. Nε-modified impurities may co-elute with KPV under a shallow ion-pair gradient if the method was not challenged with lysine-modified markers.
Published hydrogel work that incorporates KPV as a cargo is relevant to sample-preparation and recovery, not to a use recommendation. Sun and co-workers described a self-cross-linked cysteamine-grafted γ-polyglutamic acid hydrogel in which the tripeptide was incorporated in a polymeric network (PMID:34547895). A cationic tripeptide can interact with carboxylate-rich polymers and thiol-containing networks, so unvalidated plasticware or filters may adsorb analyte and bias assay recovery. HPLC sample preparation should use qualified diluents and, where adsorption is suspected, compare glass and low-bind plastics.
Related-substance reporting should list each impurity above the reporting threshold with a relative retention time and, when LC-MS is available, a proposed mass. Unidentified 214 nm peaks are common for tripeptides and should be carried as unidentified related substances rather than discarded during integration. Plausible process impurities include Nα-acetyl-KPV, Nε-acetyl-KPV, des-Val diketopiperazine cyclo(Lys-Pro), and deletion peptides. The dimeric peptide (CKPV)2 is a different chemical entity and must not be accepted as KPV on the basis of a similar letter code (PMID:16413580). Specifications should name the sequence explicitly.
What supplier-evaluation criteria distinguish research KPV lots in Australia?
Supplier evaluation when laboratories buy KPV Australia is a transparency and lot-control exercise. Compare vendors on whether the CoA is per-lot or generic, whether raw HPLC and MS files are supplied, whether the salt form and net peptide content are stated, and whether the sequence is printed rather than implied by a catalogue code. Local stock and a batch file attached to the consignment are practical Australian differentiators. Headline price per milligram is not comparable until HPLC purity, counter-ion and water are normalised; a lower gross price with unspecified trifluoroacetate content can deliver less peptide per vial.
Confirm that the molecular weight and sequence on the CoA match Lys-Pro-Val rather than a longer melanocortin analogue. Literature on α-MSH-related peptides covers many chain lengths; KPV is specifically the 11–13 tripeptide (PMID:21222263; PMID:15102092). A listing that confuses KPV with intact α-MSH or with (CKPV)2 is an identity failure at the catalogue stage. Reviews that group α-MSH-related peptides as a structural family are useful for nomenclature hygiene, not for substituting one sequence for another (PMID:12851308).
Bulk or wholesale requests should remain lot-homogeneous: one filling lot, one HPLC/MS package, vial labels that carry that lot. Independent confirmatory LC-MS on a retained vial is proportionate when the peptide will be used as a chromatographic standard. Research-only language on the invoice and CoA should match the laboratory’s intended use. Reject supply that lacks a lot number, reuses a single chromatogram across dates, reports purity without a wavelength, or omits mass-spectrometric identity. The decisive check is whether this lot’s CoA demonstrates that the solid is Lys-Pro-Val, at a stated HPLC purity, with a stated salt and a traceable lot identifier.
Order Kpv with documentation
If this guide helped you evaluate Kpv for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Kpv card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
What chemical sequence should appear on a CoA when you buy KPV Australia?
The CoA should print Lys-Pro-Val (KPV), a molecular formula or mass consistent with that tripeptide, and a lot number matching the vial. Chemical literature numbers the motif as α-MSH(11–13), which is a structural identifier only (PMID:15102092). The peptide is supplied for laboratory research use only.
Why is HPLC at 280 nm unsuitable for KPV purity?
KPV has no aromatic residues, so 280 nm absorbance is negligible. Purity HPLC should use peptide-bond detection near 210–220 nm, with ion-pairing as needed for retention on reversed-phase media, and mass spectrometry to confirm that the ultraviolet peak is the intended Lys-Pro-Val mass rather than a co-eluting related substance.
Which documents should accompany an Australian research shipment of KPV?
A lot-specific CoA, the HPLC chromatogram, the MS identity result, and a dispatch note that repeats the lot identifier. Local AU stock and tracked dispatch support chain-of-custody records; they do not replace analytical data. Archive those files with the laboratory’s incoming-goods documentation.
Is research KPV the same substance as α-MSH?
No. KPV is the three-residue carboxyl-terminal fragment corresponding to α-MSH(11–13), not the full tridecapeptide (PMID:21222263). Catalogue codes must not be substituted across chain lengths. Mass spectrometry and a printed sequence on the CoA are the practical discriminators. Request the observed m/z so the listing cannot be fulfilled with a longer melanocortin analogue.
How should lysine-modified analogues be treated during QC?
Treat them as different chemical entities. Reductive glycoalkylation and acylation at lysine change mass and retention relative to parent KPV (PMID:29953505). Such analogues fail identity for Lys-Pro-Val even if an ultraviolet peak is present. LC-MS and a lysine-sensitive related-substance method are the appropriate controls.
Can a generic catalogue chromatogram replace a lot CoA?
No. Purity and identity are lot attributes. A recycled catalogue chromatogram cannot be reconciled to a vial and should not be accepted as batch documentation. Demand a CoA whose lot number matches the vial label and the dispatch note. Per-lot HPLC and MS files are the minimum reviewable evidence.
References
- PMID:15102092 — alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells — J Invest Dermatol — 2004
- PMID:21222263 — Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore — Adv Exp Med Biol — 2010
- PMID:12851308 — New insights into the functions of alpha-MSH and related peptides in the immune system — Ann N Y Acad Sci — 2003
- PMID:29953505 — Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue — PLoS One — 2018
- PMID:34547895 — Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats — ACS Biomater Sci Eng — 2021
- PMID:16413580 — Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions — J Surg Res — 2006
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
